Delving into the Latest Updates on PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Biosimilar, Colony-stimulating factors

Synonyms-

Target

CSF-3R

Mechanism

CSF-3R agonists(Colony stimulating factor 3 receptor agonists)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Neutropenia

Originator Organization

Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

Active Organization-

Inactive Organization

Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

Drug Highest PhaseSuspendedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 4190

The sequence is quoted from: *****

观察健康受试者接受单次皮下注射聚乙二醇化重组人粒细胞集落刺激因子注射液的安全性，耐受性，评估该药的安全剂量范围，考察本品在健康人的药代动力学和药效学特点，确定健康人体的最大耐受剂量，为本品后期临床研究提供依据。

[Translation]

To observe the safety and tolerability of a single subcutaneous injection of pegylated recombinant human granulocyte colony stimulating factor injection in healthy subjects, evaluate the safe dosage range of the drug, investigate the pharmacokinetic and pharmacodynamic characteristics of this product in healthy subjects, determine the maximum tolerated dose in healthy subjects, and provide a basis for the later clinical research of this product.

Start Date03 Dec 2020

Sponsor / Collaborator

Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.

100 Clinical Results associated with PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.)

Login to view more data

100 Translational Medicine associated with PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.)

Login to view more data

100 Deals associated with PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor(Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neutropenia	Phase 1	CN	Shenzhen Sinobioway Xinpeng Biomedicine Co., Ltd.	03 Dec 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CSCO2022	Not Applicable	Esophageal Carcinoma \| Non-Small Cell Lung Cancer \| Uterine Cervical Cancer ... View more	41	PEG-rhG-CSF	aoixfqjflm(krmgsbkegy) = ujeftlrvor hlxkohzzis (njiadgealt )	-	21 Sep 2022
CSCO2022	Not Applicable	-	45	CapeOX	nwidtwmghg(luohsjbotc) = nijcvsvbup kvwacjgeqv (kpegbyxlfo ) View more	-	21 Sep 2022
CSCO2022	Not Applicable	-	45	SOX	nwidtwmghg(luohsjbotc) = lmtbbpanqm kvwacjgeqv (kpegbyxlfo )	-	21 Sep 2022
CSCO2020	Not Applicable	Non-Hodgkin Lymphoma	104	PEG-rhG-CSF	uxkauzhtct(hntmxmbvox) = lvrirxhqsr ddhaenscqh (yuopionqea ) View more	-	19 Sep 2020
CSCO2020	Not Applicable	Non-Small Cell Lung Cancer	77	PEG-rhG-CSF	etjepjlrgy(aexakbgbtv) = zyuflvigfg hnoopnkmyh (lvfxkuneyf ) View more	-	19 Sep 2020
CSCO2020	Not Applicable	Non-Small Cell Lung Cancer	77	聚乙二醇化重组人粒细胞刺激因子注射液(PEG-rhG-CSF) (Control)	etjepjlrgy(aexakbgbtv) = htmnkcxmyj hnoopnkmyh (lvfxkuneyf ) View more	-	19 Sep 2020
CSCO2020	Not Applicable	Uterine Cervical Cancer	15	PEG-rhG-CSF	ksjuluatql(ktvamrqaiq) = nvgiotsdzr ouadzpebyp (zxfmtxgyaz )	-	19 Sep 2020
CSCO2020	Not Applicable	Neutropenia \| Head and Neck Neoplasms	20	PEG-rhG-CSF	sqazpoocfm(twopwhotcr) = 发生率20-50% ychpsznmiu (yndbhptvkj ) View more	-	19 Sep 2020
ASCO2020	Not Applicable	Neutropenia	30	PEG-rhG-CSF	stcyyokmkd(hkigbnxvya) = uyclgpkuce nsikwhmful (zjrpbskhug ) View more	Positive	25 May 2020
ASCO2020	Not Applicable	Neutropenia	30	PEGylated recombinant human granulocyte stimulating factor (Control)	stcyyokmkd(hkigbnxvya) = szowzipude nsikwhmful (zjrpbskhug ) View more	Positive	25 May 2020